GH241220C32000
- 3.92
- 0.000.00%
Guardant Health Newsroom
Manulife Singapore Partners With Guardant Health to Provide Cancer Treatments
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Investors in Guardant Health (NASDAQ:GH) From Three Years Ago Are Still Down 61%, Even After 8.6% Gain This Past Week
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Express News | Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Express News | Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Express News | Natera Issues Statement on Guardant Health Litigation
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Guardant Health, Inc. (GH): Among the Most Promising Cancer Stocks According to Hedge Funds
Guardant Health (GH) Set To Dominate The Growing Liquid Biopsy Market
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avails Medical Welcomes Dan Douglas as Vice President of Finance
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Scotiabank Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $47
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $34 to $60
Guardant Health (GH) Gets a Buy From Scotiabank
Guardant Health Price Target Raised to $50.00/Share From $48.00 by JP Morgan